interim director, Nossal Institute of Global Health. Previously he held positions at the Walter and Eliza Hall Institute of Medical Research and was head of the Division of Infection and Immunity. He received his M.B.B.S. (first class honors in Medicine) and Ph.D. from the University of Melbourne, and M.P.H. from Harvard University. In addition to his clinical expertise in tropical medicine and infectious diseases, Dr. Brown was a member of the team that developed combination B vaccine and protocols for the first phase 2 clinical trial of a blood-stage malaria vaccine in Papua New Guinea in 1998. He is author or coauthor of 187 publications. Dr. Brown was formerly a member of the Strategic Advisory Council of the Bill and Melinda Gates Children’s Vaccine Program. He currently serves on numerous advisory boards including the Malaria Vaccine Advisory Committee of WHO and the Scientific Consultants Group of the USAID Malaria Vaccine Development Program.

MICHAEL F. GOOD, M.D., Ph.D., is director of the Queensland Institute of Medical Research (QIMR), Brisbane, Australia, an institution with a longstanding major focus on tropical diseases (especially malaria) and vaccine research. QIMR has conducted Phase 1 and Phase 2 malaria vaccine trials with partners in Papua New Guinea and collaborates extensively with the biotechnology industry. Prior to his appointment as director in 2000, Dr. Good was director of the Cooperative Research Centre for Vaccine Technology at QIMR. Dr. Good received his B.Sc. and M.D. from the University of Queensland and Ph.D. from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, after which he undertook postdoctoral training followed by a visiting scientist position in the Laboratory of Parasitic Diseases at the NIH (1985–1988). Dr. Good has an outstanding research record with over 220 publications, and he has been awarded the prestigious Fulbright and Neil Hamilton Fairley Fellow-ships. He is the immediate past president of the Association of Australian Medical Research Institutes. His major contributions and research interests lie in the areas of immunity, immunopathogenesis and vaccine development for malaria and group A streptococcus/rheumatic fever.

DAVID C. KASLOW, M.D., is chief scientific officer of Vical Inc., where he oversees research and development, including discovery, clinical, regulatory and quality functions for Vical’s pharmaceutical product candidates for infectious diseases and cancer based on patented gene delivery technology. Dr. Kaslow has an outstanding research career during which he has led research groups at the National Institutes of Health and at Merck & Co., with extensive experience in vaccines and malaria. He received a B.S. in biochemistry from the University of California, Davis, and M.D. from University of California, San Francisco, followed by a fellowship in

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement